The enhanced activation of CD8+ T cell response was also observed when Flagrp170 complexed with breast cancer antigen Her2/neu (Figure 2D), further supporting the increased capacity of Flagrp170 in antigen cross-presentation and T cell stimulation. This evidence concerns the gene CD8A and cancer.